CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	6 Months Ended		191 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012
Cash flows from operating activities:
Net loss	$ (6,532)	$ (8,140)	$ (260,081)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of interest on notes payable, net of amortization of debt premium			100
Amortization of investment premiums, net			(2,297)
Change in valuation of Economic Rights	(90)		(90)
Change in valuation of other liabilities measured at fair value	(50)	(203)	(6,377)
Depreciation and amortization	30	172	12,585
Amortization of intangible assets			886
Fixed asset impairment			221
Unrealized foreign exchange loss		21	7,747
Deferred revenue			(98)
Compensation for warrants issued to non-employees			1,215
Shares issued for IP rights			446
(Gain) loss on disposal of property, plant and equipment	(62)		38
Goodwill and intangibles impairment			7,934
Stock based compensation	211	455	19,234
Provision for restructuring			1,779
Amortization of issuance costs of Preferred Ordinary "C" shares			2,517
Transaction costs on sale of Economic Rights	33		33
Changes in operating assets and liabilities:
Prepaid expenses, inventory and other current assets	(307)	(279)	(365)
Accounts payable, accrued liabilities and other current liabilities	(709)	(482)	(6,022)
Net cash used in operating activities	(7,476)	(8,456)	(220,595)
Investing activities:
Purchase of ALIGN			(3,763)
Purchase of property, plant and equipment	(10)		(8,847)
Proceeds from sale of property, plant and equipment	62		225
Purchase of short-term investments			(156,657)
Redemptions of short-term investments, net of maturities			162,729
Net cash provided by (used in) investing activities	52		(6,313)
Financing activities:
Payment of capital lease obligations			(3,719)
Proceeds from issuance of ordinary and preferred ordinary shares, net of issuance costs			121,678
Proceeds from issuance of common stock, warrants and economic rights, net of issuance costs	2,886	(80)	94,557
Net proceeds from stock options and warrants exercised	34	3	207
Payment of preferred stock dividend		(364)	(1,898)
Repayment of government loan			(455)
Government loan received			414
Loan received from Cyclacel Group Plc			9,103
Proceeds of committable loan notes issued from shareholders			8,883
Loans received from shareholders			1,645
Cash and cash equivalents assumed on stock purchase			17,915
Costs associated with stock purchase			(1,951)
Net cash (used in) provided by financing activities	2,920	(441)	246,379
Effect of exchange rate changes on cash and cash equivalents	19	16	493
Net increase (decrease) in cash and cash equivalents	(4,485)	(8,881)	19,964
Cash and cash equivalents at beginning of period	24,449	29,495
Cash and cash equivalents at end of period	19,964	20,614	19,964
Cash received during the period for:
Interest	8	11	11,754
Taxes			18,207
Cash paid during the period for:
Interest			(1,914)
Schedule of non-cash transactions:
Acquisitions of equipment purchased through capital leases			3,470
Issuance of common shares in connection with license agreements			592
Issuance of ordinary shares on conversion of bridging loan			1,638
Issuance of preferred ordinary "C" shares on conversion of secured convertible loan notes and accrued interest			8,893
Issuance of ordinary shares in lieu of cash bonus			164
Issuance of other long term payable on ALIGN acquisition			$ 1,122